CD8A and melanoma: In patients with unresectable stage III or IV melanoma treated with ipilimumab, higher pretreatment levels of PD-L1+ CD8 T cells in peripheral blood were correlated with poor overall survival (OS), while showing a marginal association with ipilimumab response [26].